UPDATE; 10-12-2021
$abus uptrend wedge, inverted head & shoulder too.
[-chart]charts.stocktwits.com/production/original_385257980.jpg[/chart]
UPDATE; 10-09-2021
$ABUS COURTESY OF
$ABUS HEARING VIDEO Twitter Spaces re Moderna v Arbutus Patent Appeal Oral Argument 460 viewsOct 7, 2021 https://www.youtube.com/watch?v=3duSGLOygX0&ab_channel=DanRavicher UPDATE;
Reviewing 10-06-2021 $ABUS FACTS: & $ABUS WOW FOR INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!
ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant
AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE
UPDATE;09-27-2021
ABUS and Roivant launched Genevant as a joint venture in 2018. Roivant will begin trading as ROIV this Friday, assuming its' merger with the MAAC SPAC is approved Tuesday. Since Genevant is 60% owned by Roivant and 40% owned by ABUS, it sits under the Roivant banner as one of the Roivant Vants.
There were no shares spun off because Genevant remains private. From https://www.dcatvci.org/6162-emerging-pharma-roivant-sciences-on-the-rise "Vivek Ramaswamy is leading a family of companies that include multiple wholly owned or majority-owned subsidiaries (so-called “Vants”),
each focused on a different disease area or technology that supports the process of developing and commercializing medicines.
The company employs a “hub and spoke” model for research and development, whereby each biopharmaceutical subsidiary functions as
an independent entity (“spoke”) using shared resources from the parent (“hub”)
and the technology-based subsidiaries focused on different aspects of data science." https://www.globenewswire.com/en/news-release/2018/04/11/1468874/14025/en/Arbutus-and-Roivant-Launch-Genevant-Sciences-with-Industry-Leading-Platform-to-Develop-Broad-Range-of-RNA-Therapeutics-for-Genetic-Diseases.html "Under the terms of the agreement, Roivant will contribute $37.5 million in transaction-related seed capital for Genevant.
Roivant is committed to financially support Genevant in its aim to advance 5 to 10 product candidates into the clinic by 2020.
Arbutus will retain all rights to the LNP and conjugate delivery platforms for HBV,
and will be entitled to a tiered royalty from Genevant on future sales of products enabled by those delivery platforms.
Arbutus will also retain the entirety of its royalty entitlement on the commercialization of Alnylam’s patisiran,
which could see regulatory approval as early as the second half of 2018." In April 2018, Arbutus and Roivant Sciences Ltd. (its largest shareholder) launched the spinoff Genevant Sciences Ltd. (“Genevant”).
Under the terms of that deal, Arbutus licensed exclusive rights to its non-HBV LNP technology to Genevant (including the ‘069 patent)
and took a minority 40% common equity share in Genevant, compared to Roivant’s 60% share. 'COMPANY ORGANIZATION CHART' 09-26-2021
$ABUS [-chart]charts.stocktwits.com/production/original_383829800.png[/chart]
UPDATE; 09-10-2021
Target Price 5.90 [WITHOUT INFRINGEMENT PATENT
https://finviz.com/quote.ashx?t=ABUS
UPDATE; 09-10-2021
Arbutus rises 15% on apparent patent fight win with Moderna
http://www.arbutusbio.com/ 
http://www.arbutusbio.com/about-arbutus/overview.php https://investor.arbutusbio.com/scientific-advisory-board http://www.arbutusbio.com/about-hbv/hbv-science.php PARTNERS
http://www.arbutusbio.com/portfolio/genevant.php http://www.arbutusbio.com/partners/partnerships.php http://www.arbutusbio.com/partners/hbv-partnerships.php https://investor.arbutusbio.com/press-releases UPDATE; 04-27-2021
#2 $ABUS
FACTS: & $ABUS WOW FOR DIS INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!
ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS 1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant
AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE
11-17-2020
Chardan Capital Remains a Buy on Arbutus Biopharma (ABUS).
https://www.smarteranalyst.com/new-blurbs/chardan-capital-remains-a-buy-on-arbutus-biopharma-abus/?mod=mw_quote_news
11-17-2020
$ABUS [B.Riley Financial Keeps a Buy Rating on Arbutus Biopharma (ABUS).]
https://www.smarteranalyst.com/new-blurbs/b-riley-financial-keeps-a-buy-rating-on-arbutus-biopharma-abus/?mod=mw_quote_news
$ABUS #2 RATING $8 JMP Securities Initiates Coverage on Arbutus Biopharma (NASDAQ:ABUS)
SHARE
MONDAY, JULY 27, 2020 | MARKETBEAT
https://www.marketbeat.com/instant-alerts/nasdaq-abus-a-buy-or-sell-right-now/
Arbutus T$MRNA &$ABUSGOOD STUFF Sunday, 26 July 2020
Moderna Must Move Quickly To Buy Arbutus
Arbutus Biopharma Corporation (ABUS)
Current Price: $4.96
Target Price: $15.00
Upside Potential: 202%
Market Cap: $342 million
Shares Outstanding: 69 million
Float: 38 million
https://value-trades.blogspot.com/
http://www
http://www.arbutusbio.com/about-arbutus/overview.php
http://www.arbutusbio.com/
http://www.arbutusbio.com/about-hbv/hbv-science.php
http://www.arbutusbio.com/about-hbv/blumberg.php
http://www.arbutusbio.com/portfolio/ab-729-galnac-rnai.php
http://www.arbutusbio.com/portfolio/capsid-inhibitors.php
http://www.arbutusbio.com/portfolio/hbv-rna-destabilizer.php $MRNA &$ABUSGOOD STUFF Sunday, 26 July 2020
https://value-trades.blogspot.com/
PARTNER;
http://www.arbutusbio.com/portfolio/genevant.php
http://www.arbutusbio.com/portfolio/gritstone.php
http://www.arbutusbio.com/portfolio/patrisiran.php
http://www.arbutusbio.com/portfolio/marqibo.php
PARTERS;
http://www.arbutusbio.com/partners/hbv-partnerships.php
http://www.arbutusbio.com/partners/partnering-licensing-opportunities.php
All Navigate to...- Any - Releases
[-chart]finviz.com/chart.ashx?t=ABUS&ty=c&ta=1&p=d&s=l[/chart] 
https://finviz.com/quote.ashx?t=ABUS&ty=c&ta=1&p=d [SHARES HAVE INCREASED SOME SINCE DIS WAS DONE 04-27-2021] $ABUS FIVE YR.
https://www.otcmarkets.com/stock/ABUS/disclosure
https://www.otcmarkets.com/stock/ABUS/news
https://www.otcmarkets.com/stock/ABUS/security
https://www.otcmarkets.com/stock/ABUS/profile
https://www.otcmarkets.com/stock/ABUS/quote
https://www.otcmarkets.com/stock/ABUS/overview 02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
